Skip to main content
GWGovwatch
CongressBillsCommitteesPresidentMoneyPulseMisconductElectionsMap
Donate

Weekly accountability digest

One email a week with new votes, moving bills, and misconduct updates. No spam.

GW

Govwatch. Public data about Congress, in one place, in plain English.

Built with public data. Not affiliated with the U.S. government.

Explore

  • Officials
  • Legislation
  • Committees
  • Congress Pulse
  • Trending Topics
  • Bipartisan Leaderboard
  • Weekly Digest
  • Misconduct
  • Predictions

Learn

  • How Congress Works
  • How a Bill Becomes Law
  • Campaign Finance 101
  • Glossary

Tools

  • My Representatives
  • Compare Members
  • Bill Watchlist
  • Search
  • District Map
  • Follow the Money
  • Watch Live

Site

  • About
  • Contact
  • Corrections
  • Privacy Policy
  • Terms of Service

Data Sources

Congress.gov API v3
Bills, members, votes
GovInfo API
Floor speeches, reports, bill text
Federal Election Commission (FEC)
Campaign finance
VoteView (UCLA)
Ideology scores (DW-NOMINATE)
GovTrack.us
Misconduct data (CC0)
U.S. Census Bureau
District demographics

Data Last Updated

Bills & Votes: 5 hours ago
Support This Project

This site is free. Donations help cover hosting, API fees, and keeping the data fresh.

All data is sourced from official government APIs and public records. This site is for informational purposes only.

© 2026 Govwatch

HR5415Referred to Committee

Nitazene Control Act of 2025

Share:
Introduced
In Committee
3
Passed One Chamber
4
Passed Both
5
Signed into Law
119th
Congress
2025-09-16
Introduced
30
Cosponsors
HR
ⓘ
Type

Sponsor

Eugene Simon Vindman
Eugene Simon Vindman
Democrat · VA · Representative
Votes with party: 90.5% (603 recorded votes)
Top industries funding sponsor:
  • Veterans$4,000k

Full profile: /officials/V000138

Source: Congress.gov · FEC

Cosponsors (30)

Members who have signed on to support this bill since introduction. Source: Congress.gov.

  • Michael Baumgartner (R-WA-5)Original· 2025-09-16
  • Andy Harris (R-MD-1)· 2025-10-24
  • Brian K. Fitzpatrick (R-PA-1)· 2025-11-07
  • Donald G. Davis (D-NC-1)· 2025-11-18
  • Daniel S. Goldman (D-NY-10)· 2025-11-19
  • Richard McCormick (R-GA-7)· 2025-11-19
  • David J. Taylor (R-OH-2)· 2025-11-28
  • Ryan Mackenzie (R-PA-7)· 2025-12-10
  • Deborah K. Ross (D-NC-2)· 2025-12-16
  • Glenn Thompson (R-PA-15)· 2025-12-16
  • Mike Kelly (R-PA-16)· 2025-12-16
  • Pat Harrigan (R-NC-10)· 2025-12-16
  • Robert F. Onder, Jr. (R-MO-3)· 2025-12-18
  • Robert P. Bresnahan, Jr. (R-PA-8)· 2025-12-18
  • Chrissy Houlahan (D-PA-6)· 2025-12-19
  • Michael Lawler (R-NY-17)· 2025-12-19
  • Joe Neguse (D-CO-2)· 2026-01-07
  • Mike Carey (R-OH-15)· 2026-01-07
  • August Pfluger (R-TX-11)· 2026-01-12
  • Brandon Gill (R-TX-26)· 2026-01-12
  • Sam T. Liccardo (D-CA-16)· 2026-01-13
  • Susie Lee (D-NV-3)· 2026-01-13
  • Derek Schmidt (R-KS-2)· 2026-02-10
  • Maria Elvira Salazar (R-FL-27)· 2026-02-13
  • James R. Baird (R-IN-4)· 2026-02-20
  • Thomas R. Suozzi (D-NY-3)· 2026-03-03
  • Randy Fine (R-FL-6)· 2026-04-15
  • Russell Fry (R-SC-7)· 2026-04-15
  • Maggie Goodlander (D-NH-2)· 2026-04-22
  • Matt Van Epps (R-TN-7)· 2026-05-11

Latest Action

The most recent step in the bill's legislative path. Committee Activity below shows referrals and reports; the full action-by-action history including floor proceedings lives at Congress.gov →

Referred to the Committee on Energy and Commerce, and in addition to the Committee on the Judiciary, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.

2025-09-16

Source: Congress.gov

Committee Activity

Currently in

  • House Committee on the JudiciaryReferred To · 2025-09-16
  • House Committee on Energy and CommerceReferred To · 2025-09-16

Previously

  • Energy and Commerce CommitteeReferred To · 2025-09-16
  • Judiciary CommitteeReferred To · 2025-09-16

Plain-English Summary

The bill would classify nitazene, a synthetic opioid, as a controlled substance under federal law, making it illegal to manufacture, distribute, or possess without authorization. This would give law enforcement tools to prosecute people involved in nitazene trafficking and production, similar to how they handle other dangerous drugs like fentanyl. The change aims to address the growing public health threat from nitazene, which has been increasingly found in illicit drug supplies and linked to overdose deaths.

AI-assisted summary generated from the official bill metadata (title, subjects, actions) sourced from Congress.gov. Cached and reviewed. Always verify against the official text linked below.

Subjects

Crime and Law Enforcement
Full bill text is not yet cached locally.
Open text viewRead on Congress.gov

Related legislation

Bills by the same sponsor or covering overlapping subjects.

  • HR9533Veterans Health Administration Personnel Transparency and Accountability Act
    Referred to Committee · 2026-06-29
  • HR9379Affordable Homes for Veterans Act of 2026
    Referred to Committee · 2026-06-18
  • HR9378Grocery Affordability Act
    Referred to Committee · 2026-06-18
  • HR9082Honesty and Trust in Service Act
    Referred to Committee · 2026-05-29